Australia’s highest court has said that naturally occurring nucleic acid molecules are not patentable, overturning a lower court ruling.
Australia’s government has said the period of data exclusivity available for biological drugs in the Trans-Pacific Partnership will be five years, despite pressure from the US to extend it to 12.
A Japanese lawyer has described a ruling by the Supreme Court of Japan as a “death sentence” for product-by-process patents and said it is a good time for drugs companies to challenge rivals’ patents.
Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Worldwide applications for pharmaceutical patents “peaked sharply” in 2014, reaching around 28,000, a report has shown.
The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.
At a Thomson Reuters event in Paris on Thursday to celebrate the European companies featured on its list of top 100 global innovators, panellists including Novartis and Philips discussed the nature of innovation and how to encourage it.
The global market for products seeking to tackle counterfeit pharmaceutical and cosmetics packaging will reach more than $80 billion by 2020, according to a report.
China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Australia could be going down the road of no longer allowing gene patents, New Zealand-based patent lawyer David Nowak said at the BIO International Convention yesterday.